Surveillance of antimalarial drug resistance in China in the 1980s–1990s by De-quan Liu
Liu Infectious Diseases of Poverty 2014, 3:8
http://www.idpjournal.com/content/3/1/8SCOPING REVIEW Open AccessSurveillance of antimalarial drug resistance in
China in the 1980s–1990s
De-quan LiuAbstract
Since the successful preparation of the microplates and the medium for field application, the resistance degree and
its geographical distribution of chloroquine-resistant Plasmodium falciparum, the fluctuation of the resistance degree
of P. falciparum to chloroquine, and the sensitivity of the parasite to commonly used antimalarial drugs were
investigated between 1980 and 2003 by the in vitro microtest and the in vivo four-week test recommended by the
World Health Organization (WHO). The results indicated that chloroquine-resistant falciparum malaria was present in
all eight provinces/autonomous regions endemic for falciparum malaria in China, and the resistance was high and
widely distributed in the Hainan and Yunnan provinces. When the use of chloroquine was stopped or administered
in a decreased quanity, the drug resistance gradually decreased. In Hainan and Yunnan, P. falciparum was still highly
resistant to chloroquine, amodiaquine and piperaquine, and sensitive to pyronaridine and artemisinin derivatives,
but the sensitivity was gradually reduced. Based on these results, principles and therapeutic regimens for antimalarial
drug use in China were formulated, the use of the antimalarials which had already developed resistance was
stopped or reduced, and recommendations to use artemisinin derivatives or compound pyronaridine to promote
a rational use of antimalarials and strengthen malaria control were made. The results showed that malaria incidence
had declined, and endemic areas of falciparum malaria have been gradually reducing since the mid-1980s.
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Both P. falciparum and P. vivax can develop drug re-
sistance, but the resistance is much more important in
P. falciparum, not only for its high rate and degree of
resistance and wide geographical distribution, but also
for its ability to cause high mortality. The resistance of
P. falciparum to quinine, proguanil and cycloguanil,
pyrimethamine, chloroquine was reported in the early
20th century, late 1940s, mid-1950s and late 1950s respect-
ively. By the end of the 1950s, chloroquine-resistant mal-
aria cases were found in Colombia and Thailand. Since
then, the chloroquine resistance of the parasite rapidly
spread to almost all falciparum malaria endemic areasCorrespondence: dqliu2002@163.com
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unless otherwise stated.except for Central America [1], and multiple drug resist-
ance appeared [2,3]. Presently, P. falciparum has devel-
oped resistance to almost all available antimalarial drugs.
In recent years, P. vivax has also developed resistance to
chloroquine [4,5]. The development of drug resistance of
malaria parasites is faster than any new drug development.
It has become a worldwide problem, causing more serious
malaria transmission in some areas or countries, recur-
rence of malaria transmission in areas where malaria
transmission was once interrupted, and a significant
increase of morbidity and mortality, as well as notice-
able increases in the cost of malaria control. Resistance
of P. falciparum to pyrimethamine, proguanil, and
cycloguanil has long been reported, but resistance to
chloroquine was reported only at later stages. Chloroquine
resistance of P. falciparum was found in the Yunnan
Province [6,7] and the Hainan Province in 1973 [8,9]
and 1974, respectively. Since then, it has spread widely
throughout the endemic areas of falciparum malaria in
China in the late 1970s to early 1980s, and either resist-
ance to new antimalarials appeared or sensitivity to drugsis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and posing a major challenge for malaria control. There-
fore, drug resistance of falciparum malaria became an
urgent issue to tackle in malaria control in China. Before
1978, the WHO standard in vivo tests [10] (seven-day or
four-week tests) were used for the assessment of drug re-
sistance, but the tests are time consuming and costly, the
patients need to be hospitalized (and are usually not com-
pliant), and the result of assessment is affected by the pa-
tients’ immunity, thus it is not applicable in large areas. In
1979, an in vitro microtechnique was recommended by
the WHO to assess drug resistance of P. falciparum,
which was simpler, fast, accurate and acceptable, and
therefore appropriate to use in a large-scale survey [11,12].
The WHO had published updated protocol for antimalar-
ial drug resistance surveillance in vivo (2003), in vitro
(2001), and genotyping method (2007) [13-15]. In 1978,
the authors had successfully established in vitro continu-
ous culture of erythrocytic stage P. falciparum, which
provided an appropriate environment for the develop-
ment of the in vitro microtechnique, including the
drug-coated plates and the medium. Based on these
technical progresses [16,17], a large-scale assessment of
drug resistance was carried out by using both in vivo
and in vitro tests between 1980 and 2003. The results of
the investigation were highly beneficial to advise on
using antimalarial drugs rationally in the malaria con-
trol program.Developing an in vitro microtechnique for determining
the sensitivity of P. falciparum to antimalarial drugs
To undertake a field survey by the in vitro microtech-
nique, it is necessary to first prepare a drug-coated plate
and a medium, both of which are applicable in the field.
The WHO developed a standard chloroquine-coated plate
and test kit in 1979 [12]. After a trial application, we found
that its medium must be made into a culture solution in
the field using a relatively cumbersome procedure. In
addition, it is easy to pollute, its success rate is low, and
the effective period is only 48 hours at 4°C. The maximum
dosage of chloroquine in a chloroquine-coated plate was
32 pmol/well, which could not inhibit the growth and de-
velopment of P. falciparum completely, and it had only
one control well for observing the growth and develop-
ment of the parasite. The WHO chloroquine-coated
microplate had 96 wells for testing 12 cases; therefore
each plate must be put into an incubator repeatedly,
which may cause an error between the before and after
results. In order to promote the application of the
technique to better understand the situation on the
drug sensitivity of P. falciparum in China, we started
to develop drug-coated plates and field applicable me-
diums in 1979.A homemade plastic plate suitable for malaria parasite
growth was selected to make the chloroquine-coated mi-
croplate. Each plate had four horizontal rows with 10
wells in each row, a total of 40 wells. The size and depth
of the well were the same as in the WHO plate. The
chloroquine diphosphate solution was filled into the wells
with reference to the dosage of the WHO chloroquine-
coated microplate, two more wells were added—one for
higher dosage and one for blank control [16]—which were
kept in an incubator for 24 hours, the wells were sealed
with plastic adhesive tape after drying, the drug-coated
plate was put into a plastic bag, and stored at room
temperature. Both laboratory and field tests indicated that
the plate was as effective as the WHO standard plate,
suitable for field use in areas with higher chloroquine
resistance, and could provide a timely observation on
the growth and development of malaria parasites. All
these factors resulted in the test success rate increasing.
When stored at room temperature for over a year, the
effect remains the same [18,19].
Based on the successful preparation of the chloroquine-
coated plate, other antimalarial drug-coated plates were
also developed, including piperaquine, pyronaridine, arte-
sunate, dihydroartemisinin, artemether, and arteether.
Consequently, we could make simultaneous determina-
tions of the sensitivity of one patient’s blood to different
antimalarials, and overcome the adverse effects on the
growth of malaria parasites due to repeatedly entering
the incubator and sealing with plastic tape. At present,
the in vitro microtechnique can be used to determine
the sensitivity of the malaria parasite to all commonly
used antimalarials.
Based on the experience with the in vitro continuous
culture of P. falciparum, and by carrying out repeated tests
and improvements, the liquid medium was prepared with
RPMI1640 powder, adding 15% type AB human serum,
then packed into sterile ampoules with 0.9 ml of the solu-
tion in each; then after lyophilization, the ampoule was
sealed and stored at 4°C. Before use, it was dissolved with
0.21% sodium bicarbonate solution (in ampoule). This
medium was plainly packed, easily prepared, and used in
field situations; one ampoule of medium for one sample.
Comparative tests demonstrated that the above home-
made lyophilized medium was better than the WHO
standard medium in supporting the growth of malaria
parasites, and the effect was kept stable for two years at
4°C [16,18,19].
Since the preparation of lyophilized medium was still
troublesome, ampoule-sealed liquid medium was prepared
later. Once it was opened, it could be immediately used
for testing, was much easier to apply in the field, and
could remain in its effective state for two months at 4°C. It
was well accepted by various institutions in the country
together with the drug-coated plates [17].
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geographical distribution
A large-scale survey on the chloroquine resistance of
P. falciparum was then carried out in the 1980s in
eight provinces/autonomous regions where falciparum
malaria was prevalent, namely Yunnan, Hainan, Guangxi,
Guizhou, Henan, Jiangsu, Anhui, and Fujian. Based on the
local endemicity of falciparum malaria, each province/
autonomous region set pilot points in counties with
high morbidity of falciparum malaria to enroll patients,
and to make an in vivo four-week test [10] and an
in vitro microtest [11,12]. Between 1981 and 1984, 466
cases from 23 counties were examined. Among them,
395 cases finished the treatment course and received
observation four weeks later; 311 out of 321 cases had
successful in vitro, and 224 cases were examined concur-
rently by in vivo and in vitro with success. The results in-
dicated that chloroquine resistance had already existed in
the eight provinces/autonomous regions, especially in
Hainan and Yunnan where falciparum malaria was se-
verely prevalent. In Hainan, 106 cases from four coun-
ties were examined by the in vivo test; 90 cases were
successful, 74 were chloroquine resistant (82.2%), and
35.1% had degree III resistance (RIII). Meanwhile, 123
cases from six counties were examined by the in vitro
microtechnique; 120 cases were successful (86 cases
were concurrently examined by the in vivo test), and
113 were chloroquine resistant (94.2%), which was more
severe in the southwestern mountainous area [8,9,20].
In Yunnan, 178 cases from four counties were examined
by the in vivo four-week test; 155 were successful and
115 (74.2%) had chloroquine resistance. Among 93 cases
from four counties examined by the in vitro microtest, 88
cases were successful (81 cased were also examined by the
in vivo test), 75 cases (85.2%) were chloroquine resistant,
and the resistance was severe in the bordering area of
southern Yunnan [6,7]. In Guangxi, of the 46 cases exam-
ined by the in vivo test, 36 were successful and only 12
cases (33.3%) were RI; 14 of the successful cases wereTable 1 Result of the assessment of the chloroquine resistanc
Province In Vivo test
No. cases examined No. resistant cases Resistance rate (
Hainan 90 74 82.2
Yunnan 155 115 74.2
Guangxi 37 12 32.4
Guizhou 31 2 6.5
Anhui 20 20 100
Henan 52 3 5.8
Jiangsu 8 0 0
Fujian 2 1 50.0sensitive. Among 28 cases examined by the in vitro
microtest, 27 were successful and 21 (77.8%) were chloro-
quine resistant. In Guizhou, 39 cases were examined by
the in vivo test; 31 were successful, two (6.5%) were RI.
Among the 34 examined by the in vitro microtest, 33 were
successful and 12 cases (36.4%) appeared to show resist-
ance. In Anhui, of the 25 cases examined by the in vivo
four-week test, 20 were successful, four were RI, and 16
were RII. All 22 cases examined by the in vitro microtest
developed resistance. In Henan, of the 62 cases examined
by the in vivo four-week test, 52 were successful and three
were RI. Of the nine cases examined by the in vitro test,
three (33.3%) were chloroquine resistant. In Jiangsu, eight
cases examined by the in vivo four-week test were sensi-
tive to chloroquine, but five out of 12 cases (41.7%) exam-
ined by the in vitro microtest showed resistance. In Fujian,
one of the two cases examined by the in vivo four-week
test was RI. The results indicated that falciparum malaria
highly resistant to chloroquine was present in Hainan and
Yunnan provinces, and falciarum malaria in southern
Guangxi and central Anhui also exhibited obvious chloro-
quine resistance, but the resistance level in these latter
two provinces was lower than that in Hainan and Yunnan,
and the chloroquine resistance in southern Henan,
Guizhou, and western Jiangsu was at its initial stage
[21] (see Table 1).
The above results indicated the corelationship between
in vivo and in vitro tests. All 135 resistant cases deter-
mined by the in vivo test were also resistant by the
in vitro test; and all 40 sensitive cases determined by the
in vitro test also proved to be sensitive by the in vivo
test. However, among the 95 sensitive cases determined
by the in vivo test, 55 cases showed resistance at differ-
ent levels by the in vitro test, indicating that some
cases could not be detected by the in vivo test; thereby,
the resistance rate by the in vitro test would often be
higher than that by the in vivo test. At the same time,
it could be seen that the higher the resistance rate by
the in vivo test, the higher the drug concentrations fore of P. falciparum
In Vitro test
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in vitro test [16].
Investigation on the fluctuation of the chloroquine
resistance of P. falciparum
Since chloroquine-resistant falciparum malaria was found
in Yunnan and Hainan in 1973 and 1974, respectively, the
resistant falciparum malaria began spreading rapidly, and
the degree of resistance kept rising, becoming widely dis-
tributed from early individual resistant cases in just five
years. In 1978, chloroquine-resistant P. falciparum was
found in all 11 counties endemic for falciparum malaria in
Hainan. Therefore, the Hainan provincial government is-
sued a document to stop the use of chloroquine for mal-
aria control from 1979 and replace it with piperaquine. In
1983, it was confirmed that chloroquine-resistant falcip-
arum malaria spread all over the falciparum malaria en-
demic areas in Yunnan. Since then, chloroquine was rarely
used, and the drugs mainly used for the control of falcip-
arum malaria were artemisinins, pyronaridine, and the No.
3 antimalarial tablet (piperaquine + sulfadoxine). In order
to understand the fluctuation of the chloroquine resist-
ance of P. falciparum after stopping or reducing the use of
chloroquine, the sensitivity of P. falciparum to chloro-
quine was investigated at one to three year intervals in the
Hainan and Yunnan provinces.
The results of the assessment in Hainan
Variations in the chloroquine-resistance rate: A total of
287 cases from the Baoyou Town of Ledong County
were examined eight times successively by the in vitro
microtest; among them 128 cases were concurrently ex-
amined by the in vivo test. The resistance rate decreased
from 97.7% in 1981 to 26.7% in 1997. Taking the 1981
rate as 100, this was a reduction of 72.7% (P < 0.01). A
total of 128 cases were examined by the in vivo four-
week test; the resistance rate decreased from 84.2% in
1981 to 18.4% in 1997, a reduction of 78.1% (P < 0.01).
In 2001, 82 cases from the Yaliang Township of Sanya City
were examined by the in vitro test; the resistance rate was
59.8%. In 2003, 16 cases from the Fubao Township of
Ledong County were examined by the in vivo four-week
test; the resistance rate was 62.5%, indicating that after
stopping the use of chloroquine, the chloroquine resist-
ance of P. falciparum followed a downward trend.
Variations in the chloroquine-resistance degree: The re-
sults by the in vitro microtest demonstrated that the mean
drug concentration for complete inhibition of schizont
maturation decreased from 10.4 ± 7.1 pmol/μl blood in
1981 to 1.6 ± 1.5 pmol/μl blood in 1997, a reduction of
84.4% (P < 0.01). This indicated that in most cases, as
the time of stopping the use of chloroquine extended,
the necessary drug concentration for complete inhib-
ition of schizont maturation decreased gradually fromthe previous higher drug concentration (>6.4 pmol/μl)
to a lower drug concentration (<1.6 pmol/μl). During
1981–1997, the former decreased from 83.3% to 6.7%, a
reduction of 92.0% (P < 0.01), and the latter increased
from 4.2% to 73.3%, an increase of 94.3% (P < 0.01). The
result of the assessment by the in vivo four-week test
demonstrated that the asexual parasite clearance time
in the blood reduced from 72 hours in 1981 to
50.7 hours in 1997, the percentage of RIII cases in the
whole spectrum of resistant cases reduced from 53.1%
in 1981 to 14.3% (P < 0.01) in 1997. In 2001, 82 cases
from the Yaliang Township of Sanya City were exam-
ined by the in vitro microtest; the results indicated that
the mean drug concentration for complete inhibition of
schizont maturation was 3.56 pmol/μl blood and in
12.5% cases, it was >6.4 pmol/μl blood. In 2003, 16
cases from the Fubao Township of Ledong County were
examined by the in vivo four-week test; the results indi-
cated that the asexual parasite clearance time in the
blood was an average of 56.9 hours and the percentage
of RIII cases was 20%, indicating that the degree of the
chloroquine resistance of P. falciparum reduced grad-
ually after the use of chloroquine was stopped [22-26].
The results of the assessment in Yunnan
Variations in the chloroquine-resistance rate: A total of
234 cases from the Mengla County were examined seven
times successively by the in vitro microtest; the resistance
rate decreased from 97.4% in 1981 to 77.8% in 1999, a re-
duction of 20.1% (P < 0.01). A total of 27 cases from the
Jinghong County were examined by the in vitro microtest;
the resistance rate was 70.4%.
Variations in the chloroquine-resistance degree: The
mean drug concentration for complete inhibition of schiz-
ont maturation decreased from 17.2 ± 12.6 pmol/μl blood
in 1981 to 4.4 ± 3.1 pmol/μl blood in 1999, a reduction of
74.4% (P < 0.01). The percentage of the cases with a
complete inhibition of schizont maturation in the drug
concentration >6.4 pmol/μl in blood decreased from 58.9%
in 1981 to 19.6% in 1999, a reduction of 66.7% (P < 0.01).
In 2002, 27 cases from the Jinghong County were exam-
ined; the mean drug concentration for complete inhibition
of schizont maturation was 4.0 ± 3.3 pmol/μl blood, and
16.6% cases had complete inhibition of schizont matur-
ation in drug concentration >6.4 pmol/μl in blood, indicat-
ing that the chloroquine-resistance rate and degree of
P. falciparum fell gradually after reduced use of chloro-
quine [26] (see Table 2).
Present situation of the sensitivity of P. falciparum to
antimalarial drugs
Due to the widespread chloroquine resistance of P. falcip-
arum, application of other antimalarial drugs increased
from 1980. In order to understand the sensitivity of the
Table 2 Variations in the chloroquine resistance of P.
falciparum (In vitro)










Hainan 1981 48 97.7 10.46 ± 7.14 83.3
1997 45 26.7 1.63 ± 1.17 6.7
Yunnan 1981 39 97.4 17.2 ± 12.6 58.9
1999 18 77.8 4.4 ± 3.1 19.5
*The mean drug concentration for complete inhibition of schizont maturation.
**Percentage of cases with complete inhibition of schizont maturation.
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rational administration of the drugs, the sensitivity of
P. falciparum to chloroquine, amodiaquine, piperaquine,
mefloquine, pyronaridine, artesunate, arteether, dihydroar-
temisinin, and quinine was examined three and five times
in Hainan and Yunnan, respectively, between 1984 and
2002. The results indicated that the P. falciparum in
the two provinces had developed resistance to seven
antimalarial drugs except for mefloquine and quinine,
and displayed relatively higher resistance to chloroquine,
amodiaquine, and piperaquine. However, the sensitivity of
P. falciparum to chloroquine was recovering. The rate and
degree of resistance to piperaquine were on the rise. In the
Hainan Province, a total of 216 cases were examined by
the in vitro test five times successively; the resistance rate
increased from 15.8% in 1985 to 72.9% in 1997, and the
mean drug concentration for complete inhibition of
schizont maturation increased from 9.7 pmol/μ in 1985
to 47.9 pmol/μl in 1997, which was almost five times
higher than it was in 1985. A total of 154 cases were
examined by the in vivo test three times succesively; the
resistance rate increased from 17.2% in 1984 to 50.0% in
1997. No RIII cases were found in 1984, but RIII cases
accounted for 71.4% of the total resistant cases in 1997.
In the Yunnan Province, 126 cases were examined by
the in vitro test three times successively; the resistance
rate increased from 21.3% in 1990 to 73.0% in 1993, and
the mean drug concentration for complete inhibition of
schizont maturation increased from 19.0 pmol/μl in
1990 to 38.0 pmol/μl in 1993, which was two to three
times higher than in 1990. The results of clinical treatmentTable 3 Sensitivity of P. falciparum to piperaquine
Province In vitro test
Year No. of cases
examined
Resistance rate (%) Inhibition concentra
(pmol/μl)*
Hainan 1985 38 15.5 9.7 ± 9.1
1997 70 72.9 47.9 ± 36.5
Yunnan 1990 47 21.3 19.0 ± 17.2
1993 37 73.0 38.0 ± 32.5
*The mean concentration of piperaquine for complete inhibition of schizont matura
**Percentage of RIII cases in total resistant cases.indicated that 50% of falciparum malaria cases in Hainan
developed resistance to piperaquine (see Table 3), and the
sensitivity to pyronaridine and artemisinin derivatives
was falling gradually. Even artemether-resistant cases
were found through clinical treatment in Yunnan [27-32].
In Hainan, the mean concentration of pyronaridine and
artesunate for complete inhibition of schizont maturation
in vitro increased by four to eight times and two to eight
times, respectively [33-37] (see Table 4).
Rational use of antimalarial drugs in China
After completion of the survey on the resistance degree
of chloroquine-resistant falciparum malaria and its geo-
graphical distribution, the results and suggestions for
improving local malaria control were reported to the
Ministry of Health and the local governments, recomm-
ening that surveillance on drug-resistant malaria be
listed as one of the important tasks in malaria control.
For those provinces/autonomous regions only with spor-
adic falciparum malaria cases, it was suggested that mos-
quito control measures were strengthened to prevent
possible focal transmission of falciparum malaria, focusing
more on migrants to prevent the spreading of the drug re-
sistance more effectively. In Hainan and Yunnan, where
critical drug resistance persisted, use of chloroquine for
falciparum malaria control should be stopped, and the
therapeutic effect of other substitutes should be moni-
tored, in order to find and contain the new development
of drug resistance in a timely fashion. Due to active im-
plementation of the control program, the number of fal-
ciparum malaria endemic provinces/autonomous regions
decreased yearly, and after 1998, falciparum malaria was
prevalent only in the Hainan and Yunnan provinces.
In order to more effectively cure malaria patients
and avoid or delay the development of drug resistance
of P. falciparum, principles and therapeutic regimens
for the application of antimalarial drugs in China were
formulated in 2000 on the basis of the drug sensitivity
of the parasite found through the surveys. They were
divided into first-line, second-line, and third-line drugs, in
order to make a reasonable and standardized application
of the drugs. Chloroquine and piperaquine were recom-
mended as the first-line drugs for endemic areas of vivaxIn vivo test
tion Year No. of cases examined Resistance rate (%) RIII (%)**
1984 64 17.2 0
1997 42 50.0 71.4
tion.
Table 4 Sensitivity of P. falciparum to pyronaridine and artesunate
Drug Province In vitro test In vivo test










Pyronaridine Hainan 1986 20 0.08 1986 42 32.9 ± 12.4 43.3 ± 23.3
1997 37 1.36 1996 13 40.2 ± 15.7 62.5 ± 28.7
Yunnan 1988 25 0.14
Artesunate Hainan 1986 18 0.028
2002 32 0.135
Yunnan 1988 24 0.038
2002 22 0.054
*The mean drug concentration for complete inhibition of schizont maturation.
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chloroquine and piperaquine were still sensitive. Artemisi-
nin derivatives and pyronaridine were recommended as
the second-line drugs for areas of falciparum malaria with
moderate or high resistance to chloroquine and pipera-
quine. Artemisinin derivatives or pyronaridine in combin-
ation with other antimalarials were recommended as the
third-line drugs for those areas where the therapeutic
effect of second-line drugs was limited [38-46]. Consider-
ing that P. falciparum in China has generally developed
resistance to chloroquine, piperaquine and sulfadoxine-
pyrimethamine, and other antimalarials, artemisinin de-
rivatives and pyronaridine have been widely used as the
first-line drugs in endemic areas of falciparum malaria.
Due to the rational and standardized use of antimalarials,
the therapeutic effect was greatly improved, malaria cases
decreased considerably from 903,802 cases in 1984 to
7,855 cases in 2010 (including 1,258 falciparum malaria
cases), and the number of falciparum malaria endemic
counties decreased from 74 in eight provinces in 1984 to
just 17 in the Yunnan Province only in 2010 [47,48].
Conclusion
Drug resistance of P. falciparum is a global problem,
especialy in Southeast Asia. In some neighboring coun-
tries, such as Thailand, Cambodia, Myanmar, India, and
Vietnam, P. falciparum has developed resistance to chlo-
roquine, sulfadoxine-pyrimethamine, mefloquine, etc., ex-
tensively. On the Thailand-Cambodia border and in
Myanmar, high multiple resistance has appeared [40,49],
and Myanmar and Thailand have reported that P. vivax
has developed resistance to chloroquine and primaquine,
respectively [4,5]. Therefore, antimalarials have been
devided into first-line drugs and second-line drugs for ra-
tional application in these countries [40]. Chloroquine,
piperaquine, pyronaridine, and artemisinin derivatives are
commonly used antimalarials in China. Chloroquine has
been used extensively for more than 50 years, and the
others are relatively new antimalarials and have been used
for over 20 years.The results of the survey indicated that there was a
certain variability of the resistance of P. falciparum to
chloroquine—the resistance rate and degree to chloro-
quine was increasing from the appearance of chloroquine-
resistant falciparum malaria cases to the early stage of
reducing or stopping the use of chloroquine. Investiga-
tions indicated that once P. falciparum developed resist-
ance to chloroquine, when mosquito vectors with strong
transmissibility existed (such as Anopheles dirus and
An. minimus), and with frequent human population move-
ment, falciparum malaria would spread rapidly. Once re-
sistance to chloroquine appeared, if the use of chloroquine
could be stopped in a timely manner, the parasite could
gradually restore its sensitivity to chloroquine under the
condition of no drug pressure, but the recovery progress
would be slow. In the Hainan Province, 18 years after
stopping the use of chloroquine, about 20–60% of the
cases still had certain resistance to chloroquine. The
process of recovery of chloroquine sensitivity firstly in-
dicated a decline of the resistance degree, then the re-
duction of the resistance rate when the resistance level
dropped below a certain level. In the first 10 years after
stopping use of chloroquine, the resistance degree fell
faster, yet the resistance rate hardly changed; however,
10 more years later, the resistance rate fell faster as
well.
In the period of extensive use of piperaquine, pyronar-
idine, artemisinin derivatives, or the No. 3 antimalarial
tablet, there were plenty of cases taking insufficient dos-
ages due to low compliance, which was also one of the
major reasons for a decrease in the sensitivity to those
drugs. It was not recommended to use artemisinin de-
rivatives and pyronaridine in endemic areas of vivax
malaria; neither for treatment, preventive medicine, or
presumptive treatment for individual cases. They were
always sensitive and effective clinically, yet the sensitivity
of P. falciparum to the drugs was in a gradual downward
trend. In order to delay the development of resistance and
protect antimalarial drugs, based on the WHO advocation
to use combination artemisinin drugs, it was suggested
Liu Infectious Diseases of Poverty 2014, 3:8 Page 7 of 8
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ation with other antimalarials [40,50,51].
Additional file
Additional file 1: Multilingual abstracts in the six official working
languages of the United Nations.
Competing interests
The author declares that they have no competing interests.
Acknowledgements
The author gratefully acknowledges Mr. Chen Pulin for helping with the
English translation of the manuscript.
Received: 27 November 2013 Accepted: 11 February 2014
Published: 24 February 2014
References
1. Payne D: Spread of chloroquine resistance in Plasmodium falciparum J.
Parasitol Today 1987, 3:241–246.
2. Suebsaeng L, Wernsdorfer WH, Rooney W: Sensitivity to quinine and
mefloquine of Plasmodium falciparum in Thailand. Bull WHO 1986,
64:759–765.
3. ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L,
Chongsuphajaisiddhi T, Webster HK, White NJ: Halofantrine versus
mefloquine in treatment of multidrug-resistant falciparum malaria.
Lancet 1993, 341:1044–1049.
4. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, Gorden J,
Lal AA, Purwokusumo AR, Harjosuwarno S, Hoffman SL: Vivax malaria
resistant to treatment and prophylaxis with chloroquine. Lancet 1993,
341:96–100.
5. Looareesuwan S, Buchachart K, Wilairatana P, Chalermrut K, Rattanapong Y,
Amradee S, Siripiphat S, Chullawichit S, Thimasan K, Ittiverakul M, Triampon
A, Walsh DS: Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med
Parasitol 1997, 91:939–943.
6. Che LG, Chen WC, Yang HL, Huang KG: Report on the survey of
geographical distribution of chloroquine-resistant strain of Plasmodium
falciparum in Yunnan province. Chin J Epidemiol 1986, 7(2):88–91. in
Chinese.
7. Yang HL, Yang PF, Dong Y, Che LG, Liu DQ, Liu RJ, Zhan B, Zhang CY, Gao
DQ: Longitudinal surveillance of the resistance of Plasmodium falciparum
to chloroquine in Yunnan Province. Chin J Parasitol Parasitic Dis 1994, 12
(1):31–33. in Chinese.
8. Cai XZ, Pang XJ, Chen WJ, Li H, Ren DX: Investigation on the sensitivity of
Plasmodium falciparum to chloroquine at Qianjia, Hainan Island. Chin J
Prev Med 1982, 16(1):6–9. in Chinese.
9. Cai XZ, Pang XJ, Zeng QQ, Chen WJ, Wang XF, Zhang HJ, Wu Z, Huang QL,
Ren DX, Liu DQ, Qiu CP: The result of 10-year investigation of
chloroquine-resistant Plasmodium falciparum in Hainan Island. Chin J
Epidemiol 1986, 7(2):92–95. in Chinese.
10. WHO Technical Report Series: Chemotherapy of malaria and resistance of
antimalarials. Geneva: Report of a WHO Scientific Group; 1973.
11. Rieckmann KH, Campbell GH, Sax LJ, Mrema JE: Drug sensitivity of
Plasmodium falciparum. An in-vitro microtechnique. Lancet 1978, 1:22–23.
12. WHO: Instruction for use of the microtest kit for the assessment of the
response of Plasmodium falciparum to chloroquine and mefloquine in vitro.
Geneva; 1981.
13. Division of Control of Tropical Diseases: World Health Organisation. In In
vitro micro-test (Mark III) for assessment of the response of Plasmodium
falciparum to chloroquine, mefloquine, quinine, amodiaquine, sulfadoxine/
pyrimethamine and artemisinin. World Health Organization CTD/MAL/97.20
Rev; 2001:2.
14. World Health Organization: Assessment and monitoring of antimalarial drug
efficacy for the treatment of uncomplicated flaciparum malaria. WHO/HTM/
RBM/; 2003:50.
15. World Health Organization: Recommended Genotyping Procedures (RGPs)
to identify parasite populations. In Developed after an informal consultationorganized by the Medicines for Malaria Venture and cosponsored by the World
Health Organization. Amsterdam, Netherland; 2007.
16. Liu DQ, Ren DX, Liu RJ: Preparation of the lyophilized culture medium for
in vitro microtest of chloroquine-resistant Plasmodium falciparum and
improvement of chloroquine-coated plate. J Parasitol Parasitic Dis 1983, 1
(1):44–48. in Chinese.
17. Liu DQ, Ren DX, Liu RJ, Qiu CP, Gao DQ: A culture medium easy for field
test on the drug resistance of Plasmodium falciparum. Chin J Parasitol
Parasitic Dis 1989, 7(2):112–113. in Chinese.
18. Liu DQ, Ren DX Qiu CP, Liu RJ: Comparison of the efficacy of two culture
media for in vitro microtest on the sensitivity of Plasmodiumfalciparum
to chloroquine and mefloquine. Chin J Parasitol Parasitic Dis 1986, 4
(4):256–258. in Chinese.
19. Ren DX, Liu DQ, Liu RJ: Sensitivity of Plasmodium falciparum in Hainan
Island to chloroquine by the in vitro microtechnique. Acta Microbiol Sin
1981, 21:510–512. in Chinese.
20. Huang QL, Zhu Z, Ren DX, Liu DQ, Qiu CP, Liu RJ, Lin CF, Yang XP: A
successive survey on the sensitivity of Plasmodium falciparum patients to
chloroquine by in vitro microtechnique and in vivo test in Hainan Island.
Chin J Prev Med 1985, 19(4):220–222. in Chinese.
21. Liu DQ, Qiu CP, Liu RJ, Ren DX: Resistance degree of Plasmodium
falciparum to chloroquine and its geographical distribution in China.
Chin J Parasitol Parasitic Dis 1986, 4(2):81–85. in Chinese.
22. Onori E, Vu Thi P: Is Plasmodium falciparum resistance to chloroquine
reversible in absence of drug pressure? Lancet 1986, 1:319.
23. Liu DQ, Liu RJ, Ren DX, Gao DQ, Zhang CY, Qiu CP, Cai XZ, Lin CF, Liang AH:
Alteration in resistance of Plasmodium falciparum to chloroquine after
cessation of chloroquine medication for twelve years. Chin J Parasitol
Parasitic Dis 1992, 12(4):241–244. in Chinese.
24. Liu DQ, Liu RJ, Ren DX, Gao DQ, Zhang CY, Qui CP, Cai XZ, Ling CF, Song
AH, Tang X: Changes in the resistance of Plasmodium falciparum to
chloroquine in China. Bull World Health Organ 1995, 73:483–486.
25. Liu DQ, Cai XZ, Ren DX, Liu RJ, Lin SG, Zeng LH, Tang X: Changes in
chloroquine resistance of Plasmodium falciparum in Hainan province.
Chin J Parasitol Parasitic Dis 1999, 17(1):32–34. in Chinese.
26. Liu DQ, Feng XP, Yang HL, Lin SG, Chen WJ, Yang PF: Fluctuation in the
resistance of Plasmodium falciparum to chloroquine in China. Chin J
Parasitol Parasitic Dis 2005, 23(1):27–31. in Chinese.
27. Yang HL, He H: A report of one artemether-resistant falciparum malaria
case. Chin J Parasitol Parasitic Dis 1991, 9(2):125. in Chinese.
28. Yang HL, Yang PF, Liu DQ, Liu RJ, Dong Y, Zhang CY, Gao DQ, He H: In vitro
test on the sensitivity of Plasmodium falciparum to chloroquine,
pyronaridine, srtesunate and piperaquine in south Yunnan. Chin J
Parasitol Parasitic Dis 1992, 10(3):198–200. in Chinese.
29. Yang HL, Yang PF, Yang YM: In vitro test on the sensitivity of Plasmodium
falciparum to mefloquine, quinine, amodiaquine, chloroquine,
sulfadoxine/pyrimethamine and pyronaridine in south Yunnan. Chin J
Parasitol Parasitic Dis 1994, 12(2):140–142. in Chinese.
30. Yang HL, Liu DQ, Huang KG, Yang YM, Yang PF, Liao MZ, Zhang CY: In vitro
assay of the sensitivity of Plasmodium falciarum to chloroquine,
amodiaquine, piperaquine, mefloquine and quinine in Yunnan province.
Chin J Parasitol Parasitic Dis 1999, 17(1):43–45. in Chinese.
31. Yang HL, Liu DQ, Huang KG, Yang PF, Yang YM, Liao MZ, Zhang CY, Liu RJ:
In vitro assay of the sensitivity of Plasmodium falciparum to the
derivatives of artemisimin, pyronaridine and chloroquine in Yunnan.
Chin J Parasitol Parasitic Dis 1997, 15(5):292–296. in Chinese.
32. Yang HL, Liu DQ, Huang KG, Zhang CY, Li CF: Longitudinal surveillance of
the sensitivity of Plasmodium falciparum to pyronaridine in south
Yunnan. Chin J Parasitol Parasitic Dis 1998, 16(2):81–83. in Chinese.
33. Cai XZ: Investigation of piperaquine resistance of Plasmodium falciparum
and its treatment in Hainan Island. Hainan Health 1989, 17(4):4–8. in
Chinese.
34. Wu Z, Huang QL, Zhang KY: Piperaquine resistance of Plasmodium
falciparum in Hainan Island. Chin Med J (Engl) 1985, 65:483.
35. Zhang KY, Zhou JX, Wu Z, Huang QL: In vitro assay on the sensitivity of
Plasmodium falciparum to chloroquine, piperaquine, amodiaquine,
mefloquine and quinine. Chin J Parasitol Parasitic Dis 1987, 5(3):165. in
Chinese.
36. Qiu CP, Liu DQ, Liu RJ, Ren DX: Surveillane on sensitivity of Plasmodium
falciparum to pyronaridine and artesunate. Chin J PPrev Med 1982, 22:368.
in Chinese.
Liu Infectious Diseases of Poverty 2014, 3:8 Page 8 of 8
http://www.idpjournal.com/content/3/1/837. Liu DQ, Liu RJ, Zhang CY, Cai XZ, Tang X, Yang HL, Yang PF, Dong Y:
Present situation on the sensitivity of plasmodium falciparum to
antimalarial drugs in China. Chin J Parasitol Parasitic Dis 1996, 14(1):37–41.
in Chinese.
38. WHO Regional Office for the Western Pacific: Resistance of Plasmodium
falciparum and policies for treatment of falciparum malaria. In Proceeding
of the Informal consultation on monitoring resistance to antimalarial drugs in
the Mekong region. Phnom Penh, Cambodia; 2000:16–17.
39. WHO: The use of artermisinin and its derivatives as antimalarial drugs
(Archived). Geveva: Report of a Joint CTD/DMP/TDR Informal Consultation;
1998:10–12.
40. Roll Back Malaria/WHO: The use of antimalarial drugs. Geveva: Report of a
WHO Info Consultation; 2000:13–17.
41. Roll Back Malaria/WHO: Antimalarial drug combination therapy. Geveva:
Report of a WHO Tech Consultation; 2001:4–5.
42. Bunnag D, Karbwang J, Harinasuta T: Artemether in the treatment of
multiple drug resistant falciparum malaria [J]. Southeast Asian J Trop Med
Public Health 1992, 23:762–767.
43. Liu DQ, Lin SG, Feng XP, Chen WJ, Chen FL, Wu HM, Chen C, Liu J: Study
on treatment of multi-drug resistant falciparum malaria by using a
combination of dihydroartemisinin and pyronaridine. Chin J Parasitol
Parasitic Dis 2002, 20(4):193–196. in Chinese.
44. Huang QL, Ouyang WC, Zhou JX, Wu Z, Zhang KY, Huang JK, Cai XZ, Pang
XJ, Fu SG, Wang XF, Liu J: Effectiveness of amodiaquine, sulfadoxine-
pyrimethamine and combinations of these drugs for treating
chloroquine-resistant falciparum malaria in Hainan Island, China. Bull
World Health Organ 1988, 66(3):353–358.
45. Che LG, Zhang YL, Li XL, Shu WY, Zhang X, Li CF, Liu ZH: Clinical study on
the treatment of drug-resistant Plasmodium falciparum with compound
artemether tablet. Chin J Parasitic Dis Control 1995, 8(4):244–245. in
Chinese.
46. Expert Advisory Committee on Malaria, Ministry of Health, China: Principles
for antimalarial drug use in China. Chin J Parasitic Dis Control 2002, 15
(3):129–130. in Chinese.
47. Malaria Commission, Committee of Medical Sciences: Malaria situation in
the People’s Republic of China in 1984. Chin J Parasitol Parasitic Dis 1985,
3(4):241–243. in Chinese.
48. Zhou SS, Wang Y, Li Y: Malaria situation in the People’s Republic of China
in 2010. Chin J Parasitol Parasitic Dis 2011, 29(6):401–403. in Chinese.
49. Bloland PB: Drug resistance in malaria. WHO/CDS/CSR/DRS 2001, 10:6–8.
50. White NJ: Preventing antimalarial drug resistance through combinations.
Drug Res Updates 1998, 1:3–9.
51. White NJ: Antimalarial drug resistance and combination chemotherapy.
Philos Trans R Soc Lond B Biol Sci 1999, 354:739–749.
doi:10.1186/2049-9957-3-8
Cite this article as: Liu: Surveillance of antimalarial drug resistance in
China in the 1980s–1990s. Infectious Diseases of Poverty 2014 3:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
